Immunoadsorption and subsequent immunoglobulin substitution decreases myocardial gene expression of desmin in dilated cardiomyopathy
- PMID: 17924085
- DOI: 10.1007/s00109-007-0263-5
Immunoadsorption and subsequent immunoglobulin substitution decreases myocardial gene expression of desmin in dilated cardiomyopathy
Abstract
Cardiac autoantibodies play a pathogenic role in dilated cardiomyopathy (DCM). Removal of antibodies by immunoadsorption (IA) induces hemodynamic improvement in DCM patients. The present study investigated the effects of IA on myocardial gene expression of the intermediate cytoskeletal filament desmin, which is upregulated in heart failure. RNA was isolated from five explanted non-failing hearts and five explanted failing hearts of DCM patients, and myocardial gene expression of desmin was estimated by real-time polymerase chain reaction (PCR). In a case-control study in six DCM patients (LVEF < 40%, NYHA II-III), IA and subsequent IgG substitution were performed at monthly intervals until month 3. Endomyocardial biopsies (EMBs) were obtained before and after IA (after 3-6 months). From six DCM patients without IA therapy (controls), EMBs were also obtained over a comparable time interval. Expression of the desmin gene was analyzed in these EMBs by real-time PCR. In failing explanted hearts, expression of desmin was significantly increased (0.88 +/- 0.12 vs 0.45 +/- 0.15 in non-failing hearts, P < 0.05). After IA, myocardial gene expression of desmin was significantly decreased (from 0.26 +/- 0.05 [baseline] to 0.14 +/- 0.04 [P < 0.05] vs baseline and controls). Removal of antibodies by IA modulates myocardial gene expression of desmin in DCM patients.
Similar articles
-
Myocardial gene expression profiles and cardiodepressant autoantibodies predict response of patients with dilated cardiomyopathy to immunoadsorption therapy.Eur Heart J. 2013 Mar;34(9):666-75. doi: 10.1093/eurheartj/ehs330. Epub 2012 Oct 25. Eur Heart J. 2013. PMID: 23100283 Free PMC article.
-
Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study.J Am Coll Cardiol. 2000 May;35(6):1590-8. doi: 10.1016/s0735-1097(00)00568-4. J Am Coll Cardiol. 2000. PMID: 10807465 Clinical Trial.
-
Changes of myocardial gene expression and protein composition in patients with dilated cardiomyopathy after immunoadsorption with subsequent immunoglobulin substitution.Basic Res Cardiol. 2016 Sep;111(5):53. doi: 10.1007/s00395-016-0569-y. Epub 2016 Jul 13. Basic Res Cardiol. 2016. PMID: 27412778 Free PMC article. Clinical Trial.
-
Immunoadsorption as treatment option in dilated cardiomyopathy.Autoimmunity. 2008 Sep;41(6):484-9. doi: 10.1080/08916930802031173. Autoimmunity. 2008. PMID: 18781476 Review.
-
Immunoadsorption in dilated cardiomyopathy.Transfus Apher Sci. 2007 Oct;37(2):187-90. doi: 10.1016/j.transci.2007.08.008. Epub 2007 Nov 26. Transfus Apher Sci. 2007. PMID: 18036989 Review.
Cited by
-
Drug-like actions of autoantibodies against receptors of the autonomous nervous system and their impact on human heart function.Br J Pharmacol. 2012 Jun;166(3):847-57. doi: 10.1111/j.1476-5381.2012.01828.x. Br J Pharmacol. 2012. PMID: 22220626 Free PMC article. Review.
-
Standard and etiology-directed evidence-based therapies in myocarditis: state of the art and future perspectives.Heart Fail Rev. 2013 Nov;18(6):761-95. doi: 10.1007/s10741-012-9362-7. Heart Fail Rev. 2013. PMID: 23225133 Review.
-
Current treatment options in (peri)myocarditis and inflammatory cardiomyopathy.Herz. 2012 Sep;37(6):644-56. doi: 10.1007/s00059-012-3679-9. Herz. 2012. PMID: 22996288 Review.
-
The Molecular Role of Immune Cells in Dilated Cardiomyopathy.Medicina (Kaunas). 2023 Jul 5;59(7):1246. doi: 10.3390/medicina59071246. Medicina (Kaunas). 2023. PMID: 37512058 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources